Trial Profile
A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary) ; Efavirenz
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms NAMSAL
- 20 Oct 2023 Results of of a wide range of patient-reported outcomes , published in the JAIDS
- 14 Aug 2023 Results four-year longitudinal analysis of patient-reported outcomes following initiation of dolutegravir- or low-dose efavirenz-based first-line antiretroviral therapy , published in the JAIDS
- 26 Oct 2022 Results from DolPHIN-2, ADVANCE, NAMSAL and VISEND, comparing rates of virological failure (VF)and re-suppression in four randomised trials of dolutegravir (DTG), efavirenz (EFV) and protease inhibitors , presented at the 16th International Congress on Drug Therapy and HIV Infection